Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Brepocitinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    2D Structure
    Also known as: Pf-06700841, Pf-06700841 free base, Brepocitinib [usan], 1883299-62-4, 3x8387q25n, Brepocitinib (usan)
    Molecular Formula
    C18H21F2N7O
    Molecular Weight
    389.4  g/mol
    InChI Key
    BUWBRTXGQRBBHG-MJBXVCDLSA-N
    FDA UNII
    3X8387Q25N
    Brepocitinib is an orally available, selective inhibitor of non-receptor tyrosine-protein kinase TYK2 (tyrosine kinase 2) and tyrosine-protein kinase JAK1 (Janus kinase 1; JAK1) with potential immunomodulatory and anti-inflammatory activities. Upon oral administration, brepocitinib selectively binds to and inhibits the activation of TYK2 and JAK1, thereby disrupting TYK2 and JAK-1-dependent cytokine signaling. This may reduce inflammatory responses and prevent inflammation-induced damage caused by certain immunological diseases. TYK2 and JAK-1 are members of the Janus kinase family of non-receptor tyrosine kinases and are involved in signaling pathways affecting hematopoiesis, immunity and inflammation.
    1 2D Structure

    2D Structure

    2 Identification
    2.1 Computed Descriptors
    2.1.1 IUPAC Name
    [(1S)-2,2-difluorocyclopropyl]-[(1R,5S)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone
    2.1.2 InChI
    InChI=1S/C18H21F2N7O/c1-25-8-11(7-22-25)23-17-21-5-4-15(24-17)26-9-12-2-3-13(10-26)27(12)16(28)14-6-18(14,19)20/h4-5,7-8,12-14H,2-3,6,9-10H2,1H3,(H,21,23,24)/t12-,13+,14-/m0/s1
    2.1.3 InChI Key
    BUWBRTXGQRBBHG-MJBXVCDLSA-N
    2.1.4 Canonical SMILES
    CN1C=C(C=N1)NC2=NC=CC(=N2)N3CC4CCC(C3)N4C(=O)C5CC5(F)F
    2.1.5 Isomeric SMILES
    CN1C=C(C=N1)NC2=NC=CC(=N2)N3C[C@H]4CC[C@@H](C3)N4C(=O)[C@@H]5CC5(F)F
    2.2 Other Identifiers
    2.2.1 UNII
    3X8387Q25N
    2.3 Synonyms
    2.3.1 MeSH Synonyms

    1. Methanone, ((1s)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1h-pyrazol-4-yl)amino)-4-pyrimidinyl)-3,8-diazabicyclo(3.2.1)oct-8-yl)-

    2. Pf-06700841

    2.3.2 Depositor-Supplied Synonyms

    1. Pf-06700841

    2. Pf-06700841 Free Base

    3. Brepocitinib [usan]

    4. 1883299-62-4

    5. 3x8387q25n

    6. Brepocitinib (usan)

    7. [(1s)-2,2-difluorocyclopropyl]-[(1s,5r)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone

    8. [(1s)-2,2-difluorocyclopropyl][(1r,5s)-3-{2-[(1-methyl-1h-pyrazol-4-yl)amino]pyrimidin-4-yl}-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone

    9. Methanone, ((1s)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1h-pyrazol-4-yl)amino)-4-pyrimidinyl)-3,8-diazabicyclo(3.2.1)oct-8-yl)-

    10. G4j

    11. Brepocitinib [inn]

    12. Brepocitinib [who-dd]

    13. Chembl4297477

    14. Schembl17512502

    15. Unii-3x8387q25n

    16. Us9663526, Example 7

    17. Gtpl10459

    18. Bdbm329924

    19. Bcp29931

    20. Who 11169

    21. Zinc526061580

    22. Db15003

    23. Compound 23 [pmid: 30113844]

    24. Ncgc00510805-01

    25. Pf06700841

    26. D11537

    27. (1s)-2,2-difluorocyclopropyl)(3-(2-((1-methyl-1h-pyrazol-4-yl)amino)pyrimidin-4-yl)-3,8-diazabicyclo(3.2.1)octan-8-yl)methanone

    28. [(1s)-2,2-difluorocyclopropyl]-[(1r,5s)-3-[2-[(1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-3,8-diazabicyclo[3.2.1]octan-8-yl]methanone

    2.4 Create Date
    2016-04-09
    3 Chemical and Physical Properties
    Molecular Weight 389.4 g/mol
    Molecular Formula C18H21F2N7O
    XLogP31.5
    Hydrogen Bond Donor Count1
    Hydrogen Bond Acceptor Count8
    Rotatable Bond Count4
    Exact Mass389.17756464 g/mol
    Monoisotopic Mass389.17756464 g/mol
    Topological Polar Surface Area79.2 Ų
    Heavy Atom Count28
    Formal Charge0
    Complexity609
    Isotope Atom Count0
    Defined Atom Stereocenter Count3
    Undefined Atom Stereocenter Count0
    Defined Bond Stereocenter Count0
    Undefined Bond Stereocenter Count0
    Covalently Bonded Unit Count1
    4 Pharmacology and Biochemistry
    4.1 MeSH Pharmacological Classification

    Protein Kinase Inhibitors

    Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)